Careers  |  Sign In  |  Register

AML Patient Case: 50-Year-Old Software Engineer Presents With Fever and Shortness of Breath (Part 3)

Part 3 – Case Discussion & Wrap-up

Gabriel N. Mannis, MD, discusses the case of patient “F.M.” with fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A. Pollyea, MD, MS. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).

Disclosures:

Brian A. Jonas, MD, PhD, FACP
Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda
Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC
Travel Reimbursement: AbbVie

Gabriel N. Mannis, MD
Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer
Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz

Daniel A. Pollyea, MD, MS
Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS
Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas

References:

  1. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. PMID: 29860938.
  2. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.
  3. Ibrahim Aldoss, Dongyun Yang, Ahmed Aribi, Haris Ali, Karamjeet Sandhu, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 Sep; 103(9): e404–e407. doi: 10.3324/haematol.2018.188094. PMCID: PMC6119155.
  4. ASH 2020 MLL-menin inhibitor abstract: https://ash.confex.com/ash/2020/webprogram/Paper134942.html
  5. ASH 2020 Flotetuzumab abstract: https://ash.confex.com/ash/2020/webprogram/Paper134576.html

Faculty

Brian A. Jonas, MD, PhD, FACP
Brian A. Jonas, MD, PhD, FACP

Associate Professor of Medicine

Chair, Hematologic Malignancies Disease Team Committee

Division of Hematology and Oncology

University of California Davis School of Medicine

Sacramento, CA

Gabriel N. Mannis, MD
Gabriel N. Mannis, MD

Assistant Professor of Medicine

Division of Hematology

Stanford Cancer Institute

Stanford University

Stanford, CA

Daniel A. Pollyea, MD, MS
Daniel A. Pollyea, MD, MS

Associate Professor of Medicine

Clinical Director of Leukemia Services

Robert H. Allen MD Chair in Hematology Research

Division of Hematology

University of Colorado School of Medicine

Aurora, CO